Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.
Aditya Bardia, MD, MPH, FASCO
Advertisement
Aditya Bardia, MD, MPH, FASCO, is a medical oncologist at UCLA Health.
Articles by Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on datapotamab deruxtecan for patients with HR-positive/HER2-negative breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
5
